Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX110 CED in Newly Diagnosed Diffuse Midline Gliomas
NCT04264143Phase 1Completed
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTX110 in diffuse midline glioma (DMG). Primary endpoints: Incidence of Adverse Events and Maximum Tolerated Dose of MTX110 at 14 days. Started Mar 2020; status: completed.
02
Drugs
MTX110
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT04264143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264143.